Former VA Secretary, Biogen Exec On IRA And Politics, Price Clamps In Europe

A former secretary of the US Department of Veterans Affairs and a senior Biogen executive deliberated at a recent summit the unintended consequences of the US Inflation Reduction Act and politics around the legislation. They likened the first prescription drugs subject to price controls under the IRA to a “TV commercial list.”

Clockwise: David Shulkin, former Secretary of the US Department of VA; Jack Mycka , VP, pricing, reimbursement & market access, Indegene; Nicholas Simmons-Stern, head of global pricing & access, Biogen • Source: Indegene

Pharma has only itself to largely blame for nudging things towards price-setting legislation in the US, according to a former US government official.

Addressing the recent Indegene Digital Summit 2023, David Shulkin, former Secretary of the US Department of Veterans Affairs in the Trump Administration, stated that pharma’s relative inflexibility on pricing models was to blame for the Inflation Reduction Act (IRA) and the ripple effects of the legislation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America